4.01 Two development plans given in the fiscal 2024 10-K disappear from the fiscal 2025 10-K without a word
Company G · a US-listed specialty pharmaceutical company · Drafting slip
In brief
The fiscal 2024 10-K described an ongoing Phase 3 trial of [product] in Japan, with a plan to approach the Japanese regulator about a new drug application, and listed [product code], an extended-release [product], as a planned trial. Both were still in the 10-Q for the third quarter of 2025. The fiscal 2025 10-K drops both from its research narrative and from its table of key ongoing and planned projects without saying what happened, although it does explain why [product code] and [product code] ended. The next 10-Q shows the Japan program was still running.
The evidence, as filed
6 further page extracts: screenshot withheld to protect the company’s identity. The rows below say what each shows.
What the filing shows, and what the rule requires
| What the filing shows | What the rule requires |
|---|---|
The fiscal 2025 research narrative and pipeline table carry no sentence or row on the [product] Phase 3 trial in Japan or on [product code]; the fiscal 2024 10-K listed both. | One line on each, as the 10-K already gives for [product code] and [product code]: the status of the Japan trial and the regulatory engagement, and whether [product code] is still planned or has been dropped. |
Why it matters
A reader comparing the two years cannot tell whether the Japan program and [product code] were stopped, paused or simply left out; for the Japan program the later 10-Q shows it continued.
Exposure
Voluntary pipeline narrative; no filing consequence expected.
Our workings
the fiscal 2024 10-K said the company was [wording masked] planned to engage with the Japanese regulator about a potential new drug application, and listed '[product] [wording masked])' for [product code]. The 10-Q for the third quarter of 2025 repeated both. The fiscal 2025 10-K mentions neither anywhere; it does report that development of [product code] was stopped and that [product code] was discontinued. The 10-Q for the first quarter of 2026 says the company continues to generate data from the Japan trial and to work with the Japanese regulator.
the Japan program did not end, so the fiscal 2025 10-K understates the pipeline it describes rather than reporting a failure; the status of [product code] cannot be found in any filing.
Management’s best defense, and our reply
The table is headed 'key' projects, and management may have judged that a trial that missed its primary endpoint and an early-stage formulation were no longer key. Neither Item 101 nor Item 303 requires a program-by-program pipeline, and neither program is material to results. However, the same 10-K explains why [product code] and [product code] left the pipeline, the 10-Q filed three months earlier still listed both programs, and the next 10-Q again describes the Japan trial as continuing, so the silence reads as an oversight rather than a judgment; that is why it is raised only as a drafting point.
The fix
- Add one line to each pipeline section, for example: 'We continue to generate data from the Phase 3 trial of [product] in Japan and to [wording masked]', and state the current status of [product code] (continuing, paused or discontinued).
Evidence relied on
| # | What it shows | Type | Where |
|---|---|---|---|
| 1 | The fiscal 2024 MD&A describes the Japan Phase 3 trial as ongoing | Document | Form 10-K 2024 (prior year), page 82 |
| 2 | The plan stated in the fiscal 2024 10-K | Document | Form 10-K 2024 (prior year), page 82 |
| 3 | [product code] described as in development | Document | Form 10-K 2024 (prior year), page 82 |
| 4 | [product code] listed in the fiscal 2024 pipeline as a planned Phase 1 trial | Document | Form 10-K 2024 (prior year), page 83 |
| 5 | The fiscal 2025 pipeline table, which has no Japan or [product code] row | Document | Form 10-K 2025, page 87 |
| 6 | The fiscal 2025 10-K does explain a program that left the pipeline | Document | Form 10-K 2025, page 86 |
| 7 | A second dropped program that the fiscal 2025 10-K does mention | Document | Form 10-K 2025, page 94 |
| 8 | The 10-Q for the third quarter of 2025 still carried the Japan plan | Document | |
| 9 | The same 10-Q still listed [product code] as a planned trial | Document | |
| 10 | The 10-Q for the first quarter of 2026 shows the Japan program continued | Document |
Absence check
- Document
- Form 10-K 2025
- Where it would appear
- Below is a summary of our key ongoing and planned development projects
- What is missing
- any row or sentence on the [product] Phase 3 trial in Japan or on [product code]
- Pages looked at
- p.84-88 (MD&A research and development progress and pipeline table); p.17-19 (Item 1 research and development and the same pipeline table)
- Result
- 'Japan' hits p.14 and 84-85 ([product] license territory), [n] ([product] approvals), [n] ([product] patent applications), [n] ([product] approval in Japan), [n] (offices) and [n] (properties); 'new drug application' hits only p.6 (defined terms); 'Japanese', '[product code]' and 'extended-release' do not hit. None concerns the Japan trial or [product code].
Prepared by Pramanex from the company’s public SEC filings, without the company’s involvement, to show how a 10-K Pre-filing Check reads. The company is not named, and nothing on this page is a statement about any identifiable company. Observations are not an audit, review or other attestation or assurance engagement, and not legal advice. An SEC-style question is a question, not a conclusion.
Want this on your own 10-K, before you file?
Start with three free findings on your latest 10-K, or book a fixed-price 10-K Pre-filing Check.
Your next 10-K will be in draft before the audit is done.
Have it read before you file.
Start with three free findings on your latest 10-K, or book a fixed-price 10-K check. Drafts only under NDA, inside your insider trading policy.